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Abstract 
Background: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently 
emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of dis-
eases in need of more effective treatments. Different subtypes of soft tissue and bone sarcomas have been shown to 
express PD-1 ligand.
Methods: We retrospectively analyzed a cohort of patients (pts) with relapsed metastatic/unresectable sarcomas, 
who were treated with nivolumab provided under a patient assistance program from the manufacturer. Pts under-
went CT or PET/CT imaging at baseline and after at least four doses of nivolumab; RECIST 1.1 criteria were used for 
response assessment.
Results: Twenty-eight pts with soft tissue (STS, N = 24) or bone sarcoma (N = 4), received IV nivolumab 3 mg/
kg every 2 weeks from July 2015. Median age was 57 (24–78), male:female ratio was 14:14; the median number of 
nivolumab cycles was eight. Eighteen pts concomitantly received pazopanib at 400–800 mg daily. The most common 
side effect was grade 1–2 LFT elevations; grade 3–4 toxicity occurred in five patients (colitis, LFT elevations, pneumo-
nitis). Twenty-four pts received at least four cycles. We observed three partial responses: one dedifferentiated chon-
drosarcoma, one epithelioid sarcoma and one maxillary osteosarcoma (last two patients on pazopanib); nine patients 
had stable disease including three leiomyosarcomas; 12 patients had progression of disease including 4 leiomyosar-
coma. Clinical benefit (response + stability) was observed in 50% of the evaluable patients.
Conclusions: These data provide a rationale for further exploring the efficacy of nivolumab and other checkpoint 
inhibitors in soft tissue and bone sarcoma.
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Background
Soft tissue (STS) and bone sarcomas are a heterogeneous 
group of diseases with an estimated 15,000 new cases in 
the US in 2016, and more than 50 different subtypes [1, 
2]. Given their rarity and diversity, enrollment into pro-
spective clinical trials has been very challenging, even 
in the context of cooperative groups. Despite new stud-
ies elucidating the genomic basis and the sensitivity to 
chemotherapy of specific subtypes, the overall progno-
sis of patients with metastatic sarcoma remains poor in 
most cases. Since 2012, new drugs such as pazopanib, 
and for more specific subtypes, trabectedin and eribu-
lin, have been approved for patients who have relapsed 
after front line chemotherapy, but the response rates for 
these agents remains suboptimal [3]. Immunotherapy 
has recently provoked great interest in oncology after 
phase III clinical trials have shown significant efficacy 
in chemotherapy-resistant malignancies such as meta-
static melanoma or renal cell carcinoma, and activity in 
chemotherapy-sensitive histologies including non-small 
cell lung cancer, head and neck cancer, MSI-high colon 
cancer and Hodgkin’s lymphoma.
Programmed death 1 (PD-1) is a surface receptor 
expressed on activated and exhausted T cells, which 
mediates inhibition of activation, cytokine secretion and 
lytic activity upon binding with its ligands (PD-L1 and 
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PD-L2). The role of the PD-1/PDL-1 axis in suppression 
of T cell activation and its targeting through specific 
monoclonal antibodies, has been the basis for the success 
achieved in a number of clinical trials [4]. Tumor PD-L1 
expression has been reported in up to 65% of different 
subtypes of sarcomas [5]. The degree of PD-1 positivity in 
tumor-infiltrating lymphocytes (TILs) and PD-L1 expres-
sion in tumor specimens from 105 cases of soft tissue 
sarcomas, has been correlated with a poorer prognosis 
and more aggressive disease [6]. While preclinical stud-
ies and retrospective analyses of clinical data may pro-
vide a rationale for immune-mediated strategies against 
sarcoma, there are currently very limited clinical data 
to support the use of anti-PD-1 antibodies in this set-
ting. We report herein a retrospective series of twenty-
eight patients with metastatic or locally advanced soft 
tissue or bone sarcoma who received the PD-1 antibody 
nivolumab under a patient assistant program off proto-
col, with or without pazopanib. We describe for the first 
time clinical benefit in different subtypes, as shown by 
disease regression or stabilization.
Patients and methods
Between July 2015 and August 2016, twenty-eight 
patients with a diagnosis of soft tissue or bone sarcoma 
were treated with nivolumab. All patients but two, pre-
viously received one line of systemic treatment; patients 
receiving pazopanib before starting nivolumab were con-
tinued on this treatment given concern for disease flare 
after discontinuation, as described for other tyrosine 
kinase inhibitors [7]. The following data were recorded 
for all patients: gender, age, location of the primary sar-
coma, stage, median number of prior therapies, ECOG 
performance status, number of cycles of nivolumab 
administered. Nivolumab was given at the standard dose 
of 3 mg/kg IV every 2 weeks; the drug was provided by 
the manufacturer under a patient assistant program. 
Complete blood count, electrolytes, liver and kidney 
function tests were performed before each cycle of treat-
ment, more often if clinically indicated; all toxicities were 
recorded at each visit (at least every 2  weeks), as per 
NCI CTCAE v.4.0. Baseline scans consisted of PET/CT 
or CT scans with IVC, imaging was repeated every two 
or three months. Next generation sequencing to deter-
mine the presence of specific mutations in a panel of 50 
genes was performed in one patient with a dedifferenti-
ated chondrosarcoma responding to nivolumab alone; 
the polymerase chain reaction (PCR) product for spe-
cific mutations was sequenced on an Ion Torrent PGM 
instrument (Thermo Fisher Scientific, Waltham, MA). 
PD-L1 expression was assessed in selected patients who 
had evaluable tissue for testing (N = 10) and performed 
at Esoterix Genetic Laboratories (Integrated Oncology, 
New York, NY). PD-L1 positive was defined as a tumor 
proportion score (% of at least 100 viable tumor cells with 
complete or partial 1 + membrane staining) of 50% for at 
least 100 viable tumor cells exhibiting membrane stain-
ing. For PD-L1 detection, we used the PD-L1 IHC 28-8 
pharmDx assay (Dako North America Inc, CA, USA).
Results
Patients and treatment
The clinical characteristics of the patients are shown in 
Table 1. A total of 28 patients with a diagnosis of meta-
static (n = 26) or unresectable (n = 2) soft tissue or bone 
sarcoma received IV nivolumab every 2  weeks; median 
age was 57 years, female to male ratio was 14:14, ECOG 
performance status was 0–1 for 24 patients, and 2 for the 
remaining 4 patients. Eighteen patients received concom-
itant pazopanib. The median number of prior systemic 
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treatments, including neoadjuvant and adjuvant chemo-
therapy was 2 (range 0–6). Sarcoma subtypes are listed 
in Additional file 1: Table S1; twenty-four patients had a 
diagnosis of a soft tissue sarcoma with leiomyosarcoma 
(LMS) being the most common subtype (n  =  7); four 
patients had conventional osteosarcoma (OS).
Safety
Table  2 shows all the adverse events (AE); most side 
effects were grade 1–2 with a predominance of LFT 
abnormalities (8 out of 10 patients on pazopanib). Grade 
3–4 AE were experienced by four patients, all on pazo-
panib. One patient experienced grade 3 elevation of 
AST/ALT/alkaline phosphatase and grade 4 bilirubin 
elevation after two cycles of nivolumab; liver biopsy was 
consistent with drug related hepatitis; she discontinued 
treatment with normalization of bilirubin, and improve-
ment of ALT/AST to grade 1. A second patient experi-
enced grade 3 ALT elevation that improved to grade 1 
once both nivolumab and pazopanib were discontinued 
and high dose steroids (prednisone 1 mg/kg/daily) were 
administered with a slow taper over about 2  months; 
she subsequently restarted treatment with both drugs. 
A third patient had grade 4 AST/grade 3 ALT/alkaline 
phosphatase elevations with grade 3 pneumonitis that 
required intubation; he recovered after high dose ster-
oids and he was able to restart pazopanib only, after LFTs 
normalized. A fourth patient experienced grade 3 colitis 
that significantly improved with high dose steroids; she 
was restarted on treatment with both pazopanib and 
nivolumab until she progressed.
Efficacy outcomes
Twenty-four patients were evaluable for response (Fig. 1). 
Four patients were not evaluable for the following 
reasons: liver toxicity after 2 cycles (n  =  1); patients 
lost at follow up (n = 2), concomitant radiation therapy 
(n  =  1). We observed three partial responses (PR) and 
they included: a 74  year-old patient with a dedifferenti-
ated chondrosarcoma (DC), after six cycles of nivolumab 
alone with PR maintained after 26 cycles (Fig. 2a; Addi-
tional file  1: Figure S1). The NGS-tumor 50 panel only 
showed non-synonymous variants of unknown signifi-
cance for the PIK3CA and TP53 genes; PD-L1 staining 
was 20%. A second PR was observed in a 46  year-old 
female with a relapsed, OS of the left maxilla. She had 
a minimal clinical response to nivolumab given for four 
cycles; pazopanib was then added and it was given for 
only one month (Fig.  2b). The rationale to add pazo-
panib after 4 cycles of nivolumab alone, relied on the 
following considerations: (1) the original lesion showed 
abundant vascularization; (2) pazopanib targets the vas-
cular endothelial growth receptors VEGF-1, VEGFR-2, 
VEGF-3; (3) nivolumab alone was tolerated very well; (4) 
a resection of this challenging lesion could potentially 
give the best chance for a long progression free survival 
in this young patient. After one month of pazopanib, her 
facial lesion significantly regressed and the patient had 
major clinical benefit in terms of improved eating hab-
its and pain control. At that point we thought it was in 
the patient’s best interest to undergo surgery. At the time 
of resection, the tumor showed extensive necrosis and 
margins were negative. PD-L1 in this patient was <5%. A 
third PR was observed in a 24 year-old man with a proxi-
mal type epithelioid sarcoma (EpS) metastatic to the lung 
progressing on pazopanib. We decided to continue paz-
opanib given the concern for disease flare after discon-
tinuation as described for other tyrosine kinase inhibitors 
[7]. This patient had a PR after four cycles of nivolumab, 
progression (PD) due to a new lesion in the left lung after 
Table 2 Safety
Toxicity was graded as per NCI CTCAE v4.0
Pz pazopanib, 400–800 mg po daily; LFTs liver function tests abnormalities
Grade 1–2 Grade 3–4
On Pz (No.) NO Pz (No.) Total (No.) On Pz (No.) NO Pz (No.) Total (No.)
Hematologic
 Anemia 3 1 4 – – –
 Neutropenia 1 – 1 – – –
 Thrombocytopenia 1 1 2 – – –
Non-hematologic
 Diarrhea 3 3 1 1
 Pneumonitis 1 1 1 1
 Rash 3 1 4 – – –
 Hypothyroidism 6 2 8 – – –
 LFTs 8 2 10 3 3
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four additional cycles; he had further PD in the lung after 
four more cycles and nivolumab was stopped.
Nine patients had stable disease (SD): five patients 
received pazopanib plus nivolumab while four patients 
received nivolumab alone (one dedifferentiated chondro-
sarcoma, one leiomyosarcoma, one intimal sarcoma and 
one osteosarcoma).
A patient with an alveolar soft part sarcoma (ASPS) 
progressing on pazopanib, with a slight PD (~25% 
increase per RECIST criteria) after nine cycles of 
nivolumab, he is overall asymptomatic and continues 
treatment with both drugs; two patients with uterine 
LMS, both progressing on pazopanib alone, one had 
SD after five cycles (PD after 6 more) and the other SD 
after six cycles (nivolumab stopped after five more cycles 
because of pneumonitis); a patient with a LMS of the 
vulva had SD after five cycles of nivolumab alone but a 
PD after three additional cycles; a patient with an inti-
mal sarcoma (IS) of the right pulmonary artery meta-
static to both lungs, experienced a SD after six cycles 
of nivolumab alone (the primary site was not evalu-
able because previously irradiated); he had PD after 
six additional cycles but continues nivolumab because 
he is asymptomatic; a patient with a synovial sarcoma 
(SS) had a SD after four cycles, but died from compli-
cations during surgery for repair of a pulmonary artery 
pseudo-aneurysm; a patient with a maxillary OS had 
SD after five cycles of nivolumab alone (confirmed after 
a total of 16 cycles); a patient with a malignant periph-
eral sheet tumor (MPNST), on pazopanib, had stabil-
ity after four cycles but progressed after six additional 
cycles of nivolumab; a patient with a dedifferentiated 
myxoid chondrosarcoma (MC) had SD after four cycles 
of nivolumab.
Partial Response 
(PR) Stable disease (SD)
Progression of 
disease (PD)
N 3 9 12
Hystology DC, EpSOS 
IS, SS, OS, MPNST,
ASPS, 3 LMS, DC
4 LMS, SS, MC,
DSRCT, UPS, 
LPS, OS, RMS, 
EpS





















































Fig. 1 Response assessment after nivolumab. a Best responses; sarcoma subtypes and concomitant use of pazopanib are shown. b Swimmer plot 
in 24 patients who received at least four doses of nivolumab. Patients on pazopanib are indicated in bold on the Y axis with the correspondent 
histology. DC dedifferentiate chondrosarcoma; EpS epithelioid sarcoma; MC mesencymal chondrosarcoma; LPS liposarcoma; LMS leiomyosarcoma; 
ASPS alveolar soft part sarcoma; SS synovial sarcoma; IS intimal sarcoma; OS osteosarcoma; DSRCT desmoplastic small round cell tumor; MPNST 
malignant peripheral nerve sheet tumor; UPS undifferentiated pleomorphic sarcoma; RMS rhabdomyosarcoma. *Patient died
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Overall, 12 out of 24 evaluable patients had clinical 
benefit (PR + SD). Twelve patients had PD: four patients 
with LMS (three on pazopanib): one transferred care 
to another hospital after six cycles, one had PD after 
five cycles, confirmed after five more, and switched to 
another treatment, one received five cycles and died after 
an accidental fall, a last one had a PD after four cycles on 
nivolumab alone. Additional PD in patients on pazopanib 
included: one with a MC after four cycles (confirmed 
after 4 more), one with a liposarcoma (LPS) after five 
cycles (confirmed after 6 more), one with an OS after four 
cycles; a patient with a SS after six cycles complicated by 
severe pneumonitis; one patient with an undifferentiated 
pleomorphic sarcoma (UPS) of the right upper extrem-
ity after five cycles (confirmed after 7 more). Patient with 
PD on nivolumab alone included: one with a desmoplas-
tic small round cell tumor (DSRCT) after four cycles; one 
patient with a rhabdomyosarcoma (RMS) after six cycles; 
one with an EpS after 13 cycles.
Discussion
Patients with metastatic soft tissue sarcomas generally 
have a poor prognosis, with low response rates after first 
line chemotherapy [3]. Of note, the tyrosine kinase inhib-
itor pazopanib was approved by the FDA in 2012 on the 
basis of a phase III randomized trial showing improved 
PFS in the second line setting; the overall response rate 
was only 6% [8].
Multiple recent genomic studies have provided bet-
ter insight into sarcoma biology through a more accu-
rate classification by molecular subtype, identification of 
recurrent mutations in oncogenic pathways and evidence 
of epigenetic dysregulation [9]. Barretina et  al. [10] for 
example, recently provided a comprehensive database 
of sarcoma genome alterations in 207 samples of STS; 
despite their elucidation of genes and signaling pathways 
not previously associated with STS, we still lack appro-
priate pharmacologic tools for targeting specific genomic 
alterations.
Several subtypes of STS are characterized by specific 
chromosomal translocations which result in unique 
fusion proteins; while many of them function as tran-
scription factors, making their therapeutic targeting 
quite challenging, these proteins may represent attractive 
targets from an immunotherapy standpoint [11]. Immu-
nogenicity of sarcoma is supported by several preclini-
cal studies and some clinical data with human sarcoma 
specimens.
Immunotherapeutic strategies in sarcoma have 
included cytokine-based immunotherapies, treatment 
with muramyl tripeptide phosphatidyl ethanolamine in 






Fig. 2 Partial response (PR) to nivolumab in 2 patients. a PET/CT of a 74 year-old male with metastatic dedifferentiated chondrosarcoma after six 
cycles of nivolumab alone; he is maintaining a PR after 26 cycles. b 46 years-old woman with osteosarcoma, treated with nivolumab for six cycles; 
pazopanib 800 mg p.o. daily was started after 4 cycles of nivolumab. She underwent resection with negative margins
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cite a few examples, although none have appeared prom-
ising to date [12]. Our retrospective analysis shows the 
potential clinical benefit from treatment of soft tissue and 
bone sarcomas with the anti-PD1 antibody nivolumab.
This is not a prospective study, and given the retrospec-
tive nature of this series, it has several limitations; data on 
patients who received either nivolumab alone (N = 10) or 
nivolumab + pazopanib (N =  18), were pulled together 
in order to capture a possible signal of activity from 
immunotherapy (alone or in combination) that may be 
helpful for a following prospective study. Additionally, 
this is small study with multiple hystologies included: the 
largest group of patient had a diagnosis of leiomyosar-
coma (N = 7), but most subtypes are represented by only 
1 or 2 patients.
In our series we showed disease improvement or stabi-
lization in 12/24 patients evaluable for response. Eight-
een out of twenty-eight patients concomitantly received 
pazopanib, however 1 partial response was observed 
in a dedifferentiated chondrosarcoma on nivolumab 
alone. Another response was seen in a patient with an 
unresectable maxillary OS who received four cycles of 
nivolumab and only one month of pazopanib that was 
started after the 4 cycles of nivolumab. A third patient 
with an epithelioid sarcoma, progressing on pazo-
panib, had a partial response after only four cycles of 
nivolumab; unfortunately he progressed after four addi-
tional cycles. Of note, overall responses were observed 
in some subtypes that are generally resistant to tradi-
tional chemotherapy such as dedifferentiated chondro-
sarcoma and epithelioid sarcoma. Interestingly, all the 
three aforementioned patients received adjuvant radia-
tion therapy up to 20 years before, bringing up the pos-
sibility of a distant abscopal effect as hypothesized for 
other diseases such as melanoma [13].
At least three prospective phase II studies are exploring 
the role of the checkpoint inhibitors pembrolizumab and 
nivolumab in metastatic STS/bone sarcomas and/or uter-
ine LMS; preliminary data were recently presented at the 
ASCO 2016 conference for two studies. Pembrolizumab 
showed some interesting responses in undifferentiated 
pleomorphic sarcoma (4/9), liposarcoma (2/9), synovial 
(1/9), chondrosarcoma (1/6) and osteosarcoma (1/19); no 
responses were seen in LMS (0/10) and Ewing sarcoma 
(1/13) [14]. Interestingly in our series, we also observed 
a partial response in one patient with a dedifferentiated 
chondrosarcoma and a PD-L1 expression that was higher 
compared to all other tested patients (20% versus less 
than 5%); additionally, Kostine et al. [15] recently showed 
that this specific subtype of bone sarcoma expresses 
PD-L1 in association with immune-infiltrating cells and 
HLA class I in nearly 50% of cells. Immunotherapy with 
check-point inhibitors seems a particularly promising 
approach for the treatment of this rare and challenging 
histology but more data is needed.
A second prospective study is exploring nivolumab in 
12 patients with uterine LMS and showed no responses 
[16]. In our series, among seven patients with LMS we 
observed 4 PD and 3 SD. LMS is characterized by a sig-
nificant degree of morphologic and molecular hetero-
geneity and different molecular subtypes may respond 
differently to immunotherapy [17].
The combination of nivolumab and pazopanib is inter-
esting but needs dose optimization to prevent, in particu-
lar, excessive liver toxicity. Nivolumab at 2  mg/kg every 
3 weeks has been combined with pazopanib at 800 mg po 
daily in patients with renal cell carcinoma; about 70% of 
patients experienced grade 3–4 side effects, mainly LFT 
abnormalities, fatigue and diarrhea [18].
Conclusion
We describe a cohort of 28 sarcoma patients with meta-
static or unresectable soft tissue or bone sarcomas who 
were treated with the anti-PD-1 antibody nivolumab with 
or without the tyrosine kinase inhibitor pazopanib; we 
found evidence of clinical benefit with a half of the evalu-
able patients experiencing a partial response or a stabi-
lization of disease after at least 4 cycles of nivolumab. 
Given the potential activity of nivolumab alone and 
promising data when combined with pazopanib, we are 
planning a prospective, phase II randomized study of 
nivolumab alone versus nivolumab with pazopanib, in 
metastatic soft tissue and bone sarcomas; correlative 
studies will include tumor and serum sampling for cor-
relation with the clinical endpoints of response and pro-
gression-free survival.
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SS: synovial sarcoma; MPNST: malignant peripheral nerve sheet tumor; MC: 
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comitant treatment with pazopanib given at 400-800 mg po daily, are 
indicated. DC = dedifferentiate chondrosarcoma; MC = mesenchymal 
chondrosarcoma; LPS-DD = dedifferentiated liposarcoma; LMS = leio-
myosarcoma; ASPS = alveolar soft part sarcoma; SS = synovial sarcoma; 
EpS = epithelioid sarcoma; IS = intimal sarcoma; UPS = undifferenti-
ated pleomorphic sarcoma; DFSP = dermatofibrosarcoma protuberans; 
OS = osteosarcoma: MPNST = malignant peripheral nerve sheet tumor; 
DSRCT = desmoplastic small round cell tumor; RP = retroperitoneum; 
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(PR) to nivolumab in a 74 year-old male with metastatic dedifferentiated 
chondrosarcoma. This patient received 6 cycles of IV nivolumab 3 mg/kg 
every 2 weeks; he is maintaining a PR after 26 cycles.
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